Aldevron and Minaris Deepen Pact to Accelerate Cell Therapy Cures

FARGO, N.D. & PHILADELPHIA – May 11, 2026 – In a significant move to streamline the development of next-generation medicines, Aldevron and Minaris have renewed and expanded a licensing agreement designed to accelerate the creation of gene-modified cell therapies. The collaboration provides developers with immediate, off-the-shelf access to a crucial lentiviral plasmid system, aiming to untangle complex supply chains and shorten the arduous journey from laboratory discovery to clinical application for treatments like CAR-T.

This strategic alliance between Aldevron, a Danaher company and a leader in genomic medicine manufacturing, and Minaris, a global cell and gene therapy contract development and manufacturing organization (CDMO), addresses one of the most significant hurdles in the biotech revolution: the reliable, scalable production of starting materials. By combining world-class plasmid design with robust cGMP manufacturing, the partnership seeks to de-risk and expedite the development of therapies that hold the potential to treat cancers and rare genetic diseases.

The Backbone of a Revolution: Addressing a Critical Bottleneck

The promise of gene-modified cell therapies, such as CAR-T and TCR-T, has ignited hope across the medical field. These treatments involve engineering a patient's own immune cells to fight disease. However, the manufacturing process is extraordinarily complex, relying on a precise sequence of high-quality biological components. At the heart of this process are plasmids—small, circular DNA molecules—used to produce lentiviral vectors, which act as delivery vehicles to carry therapeutic genetic material into cells.

Historically, therapy developers have faced significant challenges in sourcing these critical plasmids. Long lead times, inconsistent quality, and the need to manage multiple vendors have created persistent bottlenecks, slowing down research and delaying clinical trials. The market for gene therapy starting materials, valued at nearly $2 billion in 2024, is projected to surge past $5 billion by 2030, reflecting the intense demand for solutions that can ensure speed and reliability.

The agreement centers on Aldevron’s pALD-Lenti plasmid system, a complete, four-plasmid platform optimized for producing lentiviral vectors. By making these plasmids available "off-the-shelf" at multiple quality grades—from research use to full current Good Manufacturing Practice (cGMP)—the partnership allows developers to use the same proven materials as they scale their programs from early-stage discovery to late-stage clinical trials and potential commercialization.

“Our collaboration with Minaris brings together complementary strengths—world‑class plasmid design and cGMP manufacturing innovation—in a way that reduces risk and complexity for developers at every stage of the pipeline,” said Venkata Indurthi, Chief Science Officer for Aldevron. “By delivering phase appropriate starting materials backed by deep manufacturing and quality expertise, Aldevron is helping compress development timelines and move innovative therapies from discovery to the clinic with greater speed, confidence, and scalability.”

A Partnership of Specialists: Combining Design and Manufacturing

The renewed pact builds on an established relationship with Oxgene, a Minaris brand that serves as its innovation engine. Based in London, Oxgene is renowned for its expertise in designing high-performance plasmid systems that enhance viral vector productivity. Under the agreement, developers not only gain access to Aldevron's manufacturing capabilities but also to the Oxgene Development Centre, where experts can help optimize plasmids and genes of interest to improve overall process performance.

This integration of specialized expertise is a key differentiator. Minaris, through Oxgene, provides the sophisticated engineering and design grounded in deep vector development experience. Aldevron, backed by the operational might of its parent company Danaher, contributes the large-scale, high-quality manufacturing infrastructure necessary to produce these designs consistently and in compliance with stringent global regulations.

“Our focus has always been on designing robust, high‑performing plasmid systems that translate seamlessly into scalable vector production,” stated Eytan Abraham, PhD, Chief Technology and Commercial Officer for Minaris. “By combining that design expertise with Aldevron’s manufacturing strength, we help ensure developers have reliable, high‑quality starting materials that reduce risk, streamline development, and support a clear path toward clinical and commercial success.”

Navigating the Regulatory Gauntlet

The term "regulatory-ready" is more than just a marketing buzzword; it represents a crucial advantage in the high-stakes world of drug development. Because cell and gene therapies are living treatments that cannot undergo terminal sterilization, the quality of every raw material is scrutinized intensely by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

By providing cGMP-grade plasmids with comprehensive documentation, such as a Drug Master File (DMF) that can be referenced in regulatory submissions, Aldevron and Minaris significantly lower the barrier to entry for clinical trials. This allows therapy developers, particularly smaller biotech firms that are often at the cutting edge of innovation, to avoid the time-consuming and costly process of developing and validating their own starting materials. It streamlines the Chemistry, Manufacturing, and Controls (CMC) section of an Investigational New Drug (IND) application, a frequent source of delays.

The Competitive Landscape and Broader Strategy

The move by Aldevron and Minaris does not exist in a vacuum. It reflects a powerful industry-wide trend toward simplifying the gene therapy supply chain. Other major players in the CDMO and raw materials space, including Charles River Laboratories and Sartorius, have also launched their own off-the-shelf plasmid offerings, underscoring the market's urgent need for standardized, high-quality solutions.

For Aldevron's parent company, Danaher, this deepened alliance is a clear execution of its broader strategy in genomic medicine. Danaher's $9.6 billion acquisition of Aldevron in 2021 was a landmark investment aimed at building a comprehensive ecosystem to support the development of advanced therapies. By fostering strategic partnerships that combine best-in-class technologies, Danaher is positioning itself as an indispensable partner for the entire biotechnology industry.

This collaboration exemplifies a maturing market, moving from bespoke, lab-specific processes toward industrialized solutions that enable greater scale and accessibility. By providing a reliable foundation of critical starting materials, the partnership between Aldevron and Minaris empowers innovators to focus on what they do best: designing the next wave of life-changing therapies. This strategic alignment of design and manufacturing is poised to become a standard model as the industry works to turn the immense promise of genomic medicine into a clinical reality for patients worldwide.